News
PHGE
6.19
-2.83%
-0.18
BiomX Shareholders Approve Expanded Common Stock Issuance Authorization
TipRanks · 2d ago
BiomX Cut to Neutral From Buy by HC Wainwright & Co.
Dow Jones · 4d ago
HC Wainwright & Co. Downgrades BiomX to Neutral
Benzinga · 4d ago
BiomX downgraded to Neutral from Buy at H.C. Wainwright
TipRanks · 4d ago
BiomX names Michael Oster as CEO, David Rokach as CFO
TipRanks · 4d ago
*BiomX Names Michael Oster As Chief Executive Officer, David Rokach Chief Financial Officer To Support Next Phase Of Growth >PHGE
Dow Jones · 4d ago
Weekly Report: what happened at PHGE last week (0302-0306)?
Weekly Report · 4d ago
Biomx CEO Jonathan Solomon, Chairman Russell Greig Resign, Effective March 4; Michael Oster Appointed CEO
Benzinga · 03/06 13:57
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 03/06 12:05
Biomx Inc trading resumes
TipRanks · 03/05 16:00
Biomx Inc trading halted, volatility trading pause
TipRanks · 03/05 15:55
BiomX Adjourns Special Shareholder Meeting for Lack of Quorum
TipRanks · 03/02 21:52
Weekly Report: what happened at PHGE last week (0223-0227)?
Weekly Report · 03/02 09:13
Weekly Report: what happened at PHGE last week (0216-0220)?
Weekly Report · 02/23 09:13
Weekly Report: what happened at PHGE last week (0209-0213)?
Weekly Report · 02/16 09:13
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 02/12 17:05
BiomX Restructures After Insolvency and Executive Terminations
TipRanks · 02/10 21:47
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 02/10 17:05
BiomX files to sell 5.31M shares of common stock for holders
TipRanks · 02/09 21:40
Weekly Report: what happened at PHGE last week (0202-0206)?
Weekly Report · 02/09 09:13
More
Webull provides a variety of real-time PHGE stock news. You can receive the latest news about Biomx Inc through multiple platforms. This information may help you make smarter investment decisions.
About PHGE
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).